Cover Image
市場調查報告書

不寧腿症候群 : 開發平台分析

Restless Legs Syndrome - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 192807
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
不寧腿症候群 : 開發平台分析 Restless Legs Syndrome - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 44 Pages
簡介

所謂不寧腿症候群(RLS,Restless Legs Syndrome),別名Willis-Ekbom症候群(WED),是神經系統部分障礙。對腿部起作用,會變得頻繁地想要動腳。症狀中包含發癢和疼痛、刺癢的感覺,腿和小腿部痙攣等。易罹病素質估計是老齡化。這個疾病的治療藥,為肌肉鬆弛劑和安眠藥、麻醉劑等。

本報告提供全球各國的不寧腿症候群治療用的開發中產品的開發情形相關分析、開發中產品的最新趨勢,及各臨床實驗階段的產品一覽、主要企業簡介、主要藥物概要、最新的產業趨勢等調查,並將其結果為您概述為以下內容。

目錄

簡介

  • 分析範圍

不寧腿症候群概要

治療藥的開發

  • 不寧腿症候群開發中產品:概要
  • 不寧腿症候群開發中產品:比較分析

各企業開發中的不寧腿症候群治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

不寧腿症候群治療藥:開發中的產品一覽(各企業)

開發不寧腿症候群治療藥的企業

  • Alexza Pharmaceuticals, Inc.
  • Ascendis Pharma A/S
  • 久光製藥
  • Ligand Pharmaceuticals, Inc.
  • Mundipharma International Ltd
  • Omeros Corporation
  • Serina Therapeutics, Inc.
  • Vifor Pharma AG

不寧腿症候群:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 各標靶
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • (naloxone hydrochloride+oxycodone hydrochloride)ER
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • aplindore fumarate
  • AZ-008
  • ferric carboxymaltose
  • OMS-527
  • pramipexole dihydrochloride
  • ropinirole hydrochloride
  • SER-214

不寧腿症候群治療藥:最新的藥物簡介

不寧腿症候群治療藥:開發暫停的產品

不寧腿症候群治療藥:開發中止的產品

不寧腿症候群相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9506IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Pipeline Review, H2 2017, provides an overview of the Restless Legs Syndrome (Central Nervous System) pipeline landscape.

Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling and cramping in the calf's or legs. Predisposing factor includes age. Treatment includes muscle relaxants, sleep medications and narcotic medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Restless Legs Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Restless Legs Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Restless Legs Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 1 and 2 respectively.

Restless Legs Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Restless Legs Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Restless Legs Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Restless Legs Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Restless Legs Syndrome (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Restless Legs Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Restless Legs Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Restless Legs Syndrome - Overview
    • Restless Legs Syndrome - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Restless Legs Syndrome - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Restless Legs Syndrome - Companies Involved in Therapeutics Development
    • Galenica Ltd
    • Hisamitsu Pharmaceutical Co Inc
    • Merz Pharma GmbH & Co KgaA
    • Mundipharma International Ltd
    • Omeros Corp
    • Serina Therapeutics Inc
  • Restless Legs Syndrome - Drug Profiles
    • (cannabidiol + dronabinol) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (naloxone hydrochloride + oxycodone hydrochloride) ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aplindore fumarate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ferric carboxymaltose - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • incobotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-527 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ropinirole hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SER-214 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Restless Legs Syndrome - Dormant Projects
  • Restless Legs Syndrome - Discontinued Products
  • Restless Legs Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • May 29, 2015: Napp receives approval from MHRA to prescribe Targinact (oxycodone/naloxone) for the treatment of Restless Legs
      • Jan 07, 2015: Mundipharma receives positive European Commission decision on Targin (oxycodone/naloxone) for the treatment of Restless Legs Syndrome
      • Oct 24, 2014: Mundipharma receives Positive CHMP Opinion for Targin (oxycodone / naloxone) for the treatment of Restless Legs Syndrome
      • Oct 23, 2014: Hisamitsu Announces the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome)
      • Nov 19, 2013: New data show efficacy of prolonged release TARGIN (oxycodone / naloxone) in the treatment of severe restless legs syndrome
      • Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Restless Legs Syndrome, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Restless Legs Syndrome - Pipeline by Galenica Ltd, H2 2017
  • Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2017
  • Restless Legs Syndrome - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017
  • Restless Legs Syndrome - Pipeline by Mundipharma International Ltd, H2 2017
  • Restless Legs Syndrome - Pipeline by Omeros Corp, H2 2017
  • Restless Legs Syndrome - Pipeline by Serina Therapeutics Inc, H2 2017
  • Restless Legs Syndrome - Dormant Projects, H2 2017
  • Restless Legs Syndrome - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Restless Legs Syndrome, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top